Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
J Cardiovasc Pharmacol
    January 2018
  1. PARK Y, Choi BG, Rha SW, Baek MJ, et al
    Selective ss1-Blockers Are Not Associated With New-onset Diabetes Mellitus in Hypertensive Patients.
    J Cardiovasc Pharmacol. 2018;71:38-45.
    >> Share

    November 2017
  2. REPAS SJ, Saad NS, Janssen PML, Elnakish MT, et al
    Memantine, an NMDA Receptor Antagonist, Prevents Thyroxin-induced Hypertension, but Not Cardiac Remodeling.
    J Cardiovasc Pharmacol. 2017;70:305-313.
    >> Share

    October 2017
    Antihypertensive therapy and new on-set of diabetes mellitus: The double edge sword.
    J Cardiovasc Pharmacol. 2017 Oct 31. doi: 10.1097/FJC.0000000000000553.
    >> Share

    June 2017
  4. HANSEN MS, Andersen A, Holmboe S, Schultz JG, et al
    Levosimendan prevents and reverts right ventricular failure in experimental pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2017 Jun 19. doi: 10.1097/FJC.0000000000000508.
    >> Share

    May 2017
  5. MAGUBANE M, Michel FS, Erlwanger KH, Norton GR, et al
    Prevention of betaeta-Adrenergic-Induced Adverse Cardiac Remodelling by Gonadectomy in Male but not Female Spontaneously Hypertensive Rats.
    J Cardiovasc Pharmacol. 2017 May 30. doi: 10.1097/FJC.0000000000000506.
    >> Share

  6. JAIN M, Bhosale V, Tripathi D, Singh H, et al
    Antihypertensive drugs aliskiren, nebivolol, and olmesartan reduce hypertension by reducing endothelial microparticle and regulating angiogenesis.
    J Cardiovasc Pharmacol. 2017 May 9. doi: 10.1097/FJC.0000000000000503.
    >> Share

    March 2017
  7. IZZO JL JR, Zappe DH, Jia Y, Hafeez K, et al
    Efficacy and safety of crystalline valsartan/sacubitril (LCZ696) compared to placebo and combinations of free valsartan and sacubitril in patients with systolic hypertension: the RATIO study.
    J Cardiovasc Pharmacol. 2017 Mar 23. doi: 10.1097/FJC.0000000000000485.
    >> Share

    Hypertension's 3 Dilemmas and 3 Solutions: Pharmacology of the Kidney in Hypertension.
    J Cardiovasc Pharmacol. 2017;69:129-139.
    >> Share

    Editorial for "Hypertension's 3 Dilemmas & 3 Solutions: Pharmacology of the Kidney in Hypertension".
    J Cardiovasc Pharmacol. 2017;69:127-128.
    >> Share

    October 2016
  10. CAMPOS C, Luz de Castro A, Vicente Tavares AM, Fernandes RO, et al
    Effect of free and nanoencapsulated copaiba oil on monocrotaline-induced pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2016.
    >> Share

    July 2016

  11. Morphological Identification of TRPC7 in Cardiomyocytes from Normal and Renovascular Hypertensive Rats: Retraction.
    J Cardiovasc Pharmacol. 2016;68:96.
    >> Share

    April 2016
  12. KAMIMURA D, Uchino K, Ishigami T, Hall ME, et al
    Activation of Peroxisome Proliferator-Activated Receptor gamma Prevents Development of Heart Failure with Preserved Ejection Fraction; Inhibition of Wnt-beta-catenin Signaling as a Possible Mechanism.
    J Cardiovasc Pharmacol. 2016.
    >> Share

  13. LIU X, Duan P, Hu X, Li R, et al
    Altered KATP channel subunits expression and vascular reactivity in spontaneously hypertensive rats with age.
    J Cardiovasc Pharmacol. 2016.
    >> Share

    February 2016
  14. DEMIR M, Gurol AO, Ozyigit RT, Uresin AY, et al
    Effects of Blood Pressure Lowering with Different Antihypertensive Agents on Cognitive Function and Plasma Brain-Derived Neurotrophic Factor Levels: A Comparative Study.
    J Cardiovasc Pharmacol. 2016.
    >> Share

  15. FARES WH
    Pushing the Envelope on the Indications and Doses of Pulmonary Arterial Hypertension Medications: What's Reasonable?
    J Cardiovasc Pharmacol. 2016.
    >> Share

    January 2016
  16. PARIKH KS, Rajagopal S, Fortin T, Tapson VF, et al
    Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.
    J Cardiovasc Pharmacol. 2016.
    >> Share

  17. LI Y, Geng X, Wang H, Cheng G, et al
    CTRP9 ameliorates pulmonary-arterial hypertension through attenuating inflammation and improving endothelial cell survival and function.
    J Cardiovasc Pharmacol. 2016.
    >> Share

  18. VIRDIS A, Taddei S
    Endothelial Dysfunction In Resistance Arteries Of Hypertensive Humans: Old And New Conspirators.
    J Cardiovasc Pharmacol. 2016.
    >> Share

  19. AKAGI S, Nakamura K, Matsubara H, Kondo M, et al
    Intratracheal administration of prostacyclin analog-incorporated nanoparticles ameliorates the development of monocrotaline and sugen/hypoxia-induced pulmonary arterial hypertension.
    J Cardiovasc Pharmacol. 2016.
    >> Share

    December 2015
  20. SHANG P, He ZY, Chen JF, Huang SY, et al
    Absence of the Adenosine A2A Receptor Confers Pulmonary Arterial Hypertension Through RhoA/ROCK Signaling Pathway in Mice.
    J Cardiovasc Pharmacol. 2015;66:569-75.
    >> Share

    November 2015
  21. MARTINEZ-AGUILAR L, Lezama-Martinez D, Orozco-Cortes NV, Gonzalez-Espinosa C, et al
    Antihypertensive properties of a the novel morphologic derivative (4-tert-buthyl-2,6-bis (thiomorpholine-4-ilmethyl)phenol).
    J Cardiovasc Pharmacol. 2015.
    >> Share

  22. LINZ B, Hohl M, Reil JC, Bohm M, et al
    Inhibition of NHE3-mediated sodium absorption in the gut reduced cardiac end-organ damage without deteriorating renal function in obese spontaneously hypertensive rats.
    J Cardiovasc Pharmacol. 2015.
    >> Share

    August 2015
  23. MONTO F, Oliver E, Vicente D, Buendia F, et al
    J Cardiovasc Pharmacol. 2015.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016